What Cathie Wood's Opposite Trades in Intellia and Shopify Are Really Telling You

Read the trade logs and the first reaction is predictable: wait, she's adding to the gene-editing biotech that loses money every single quarter, and trimming the e-commerce platform that just posted its best quarter in years? If you took the moves as a ranking of business quality, they'd be exactly backwards.

They aren't a ranking of business quality. They're the signature of Ark Invest's mandate — buy disruptive optionality, trim winners to keep position sizes in check — and the two stocks sit at opposite ends of what that mandate seeks. Understand which is which, and both trades stop looking contradictory and start looking like a useful lesson about copying anyone's portfolio.

Ark has been a heavy holder in Intellia all year, calling it a core gene-editing bet and continuing to add through the summer, while the Shopify position has repeatedly been sold into strength since late last year — profit-taking on a position that originally cost $297 million and has grown roughly 99%. None of this is unusual behavior for a fund with a momentum-tilted, version-2.0 thesis. The only thing that makes the pair look strange is the enormous gap in current economics between the two companies.

Shopify: the business is fine — the price did the trimming

Start with the one that looks most illogical to trim. Shopify reported its second-quarter 2026 results on August 5, and by any conventional measure the business is compounding: revenue rose 34% year over year to $3.58 billion, gross merchandise volume climbed 32% to $115.6 billion, adjusted earnings per share rose 20%, and free cash flow margin hit 18%. Management even guided the next quarter to low-thirties growth — a pace most software companies would trade a limb for.

So why does Ark keep selling it? Because the stock is priced as though all of that is already in hand. Shopify trades near $140 at roughly 14 times trailing sales, with a triple-digit trailing P/E and a market cap around $182 billion. The business is great; the margin of error between that price and any disappointment is not. Trimming a position that has already delivered roughly a double, at a multiple that leaves no room for execution error, is risk management — not a bearish thesis on the company. You can believe Shopify is a wonderful long-term business and still lighten exposure at 14x sales.

This is the half of the story the headline buries. A profitable 34%-grower being sold isn't evidence of trouble; it's evidence that the buyer wanted the gains banked while the business is bulletproof. If anything, the steady trimming is flattering to the underlying company — the question was never whether Shopify works, only what you have to pay for the privilege.

Intellia: buying a catalyst, not a cheap stock

Intellia is the mirror image, and it's where buyers across the internet need the most caution. On the surface, the stock looks like a "battered growth" story: down roughly 55% from its 52-week high of about $28, YTD still up more than 40%, with catalysts arriving. In the second quarter it reported a net loss of $106.6 million and only $7.7 million of revenue, and its entire value rests on clinical delivery rather than anything you can audit on an income statement.

The catalyst is real. Intellia's lead therapy, lonvo-z for hereditary angioedema, posted positive Phase 3 data showing an 87% reduction in attacks versus placebo, with 62% of treated patients entirely attack-free and off preventive therapy over the six-month evaluation window. The company expects FDA acceptance of its biologics application in the second half of 2026 and a U.S. launch in the first half of 2027, and it holds $628.4 million of cash it says funds operations at least into 2028. Whatever you think of the science, the timing is clean: a binary regulatory event is coming into view.

But here is the discipline Ark's trade can obscure. Intellia is priced at only about a $1.35 billion enterprise value against a $628 million cash cushion — which means the market is assigning a modest amount for the entire clinical and commercial program. That is not a sign the stock is "cheap" the way a value stock is cheap; there is no earnings to compare against, only unproven optionality. An 87% attack reduction in a high quality of life study is impressive science, but hereditary angioedema is a niche market, and the second pipeline leg in ATTR amyloidosis is years away from commercial resolution. Buying Intellia is buying a binary outcome where the payout depends on regulatory delivery through 2027 — not on a P/E converging with the market.

The lesson isn't in the tickers

That is the point the trades actually make. Ark buying Intellia says nothing about Intellia being a bargain in any value sense; it says the fund wants the catalyst optionality in a beaten-down name. And Ark trimming Shopify says nothing about Shopify's business deteriorating; it says the good news is already in the price. Both flags point in the same direction — to a portfolio manager trading the price-versus-story gap, not to a fundamental verdict on either company.

For a retail investor, the takeaway is the reverse of the instinct the headline provokes. Don't mirror the buy because Ark bought it — Intellia fails the traditional quality tests before you even reach valuation, and it is a position-sized speculation on BLA approval, not a tested gap. And don't read the trim as doubt about Shopify — the business is arguably as strong as it's ever been, and the only question is whether you want to own a great 34%-grower at 14x sales. Understand what each trade is actually purchasing, and you'll find neither is an easy copy. That separation — being able to say why a fund bought and what it bought — is the part worth taking from the logs.